Dosage modifications & management guidance for EPKINLY1

Dosage modifications for adverse reactions

If CRS or ICANS is suspected, withhold EPKINLY until symptoms resolve. For ICANS, consider neurology evaluation and rule out other causes of neurologic symptoms. Administer supportive therapy, which may include intensive care.

CRS CRS
ICANS ICANS
CRS grade* Presenting symptoms Actions

Grade 1

Temperature ≥100.4°F (38°C)†
  • Withhold EPKINLY and manage per current practice guidelines
  • Ensure CRS symptoms are resolved prior to next dose of EPKINLY‡

Grade 2

Temperature ≥100.4°F (38°C)† with:

  • Hypotension not requiring vasopressors

and/or

  • Hypoxia requiring low-flow oxygen§ by nasal cannula or blow-by
  • Withhold EPKINLY and manage per current practice guidelines
  • Ensure CRS symptoms are resolved prior to next dose of EPKINLY‡
  • Administer premedication prior to next dose of EPKINLY
  • For the next dose of EPKINLY, monitor more frequently and consider hospitalization

Grade 3

Temperature ≥100.4°F (38°C)† with:

  • Hypotension requiring a vasopressor (with or without vasopressin)

and/or

  • Hypoxia requiring high-flow oxygen§ by nasal cannula, face mask, non-rebreather mask, or Venturi mask
  • Withhold EPKINLY and manage per current practice guidelines, which may include intensive care
  • Ensure CRS symptoms are resolved prior to the next dose of EPKINLY†
  • Administer premedication¶ prior to next dose of EPKINLY
  • Hospitalize for the next dose of EPKINLY

Recurrent grade 3 CRS

  • Permanently discontinue EPKINLY
  • Manage CRS per current practice guidelines and provide supportive therapy, which may include intensive care

Grade 4

Temperature ≥100.4°F (38°C)† with:

  • Hypotension requiring multiple vasopressors (excluding vasopressin)

and/or

  • Hypoxia requiring oxygen by positive pressure (eg, CPAP, BiPAP, intubation, and mechanical ventilation)
  • Permanently discontinue EPKINLY
  • Manage CRS per current guidelines and provide supportive therapy, which may include intensive care

Presenting symptoms

Temperature ≥100.4°F (38°C)†

Actions

  • Withhold EPKINLY and manage per current practice guidelines
  • Ensure CRS symptoms are resolved prior to next dose of EPKINLY‡
ICANS grade* Presenting symptoms|| Actions

Grade 1

ICE score 7-9# or Depressed level of consciousness**:

  • Awakens spontaneously
  • Withhold EPKINLY until ICANS resolves††
  • Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management, including consideration for starting non-sedating, anti-seizure medicines for seizure prophylaxis

Grade 2

ICE score 3-6# or Depressed level of consciousness**:

  • Awakens to voice
  • Withhold EPKINLY until ICANS resolves††
  • Administer dexamethasone‡‡ 10 mg intravenously every 6 hours. Continue dexamethasone use until resolution to grade 1 or less, then taper
  • Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management, including consideration for starting non-sedating, anti-seizure medicines for seizure prophylaxis

Grade 3

ICE score 0-2# or Depressed level of consciousness**:

  • Awakens only to tactile stimulus

or Seizures,** either:

  • Any clinical seizure, focal or generalized, that resolves rapidly, or
  • Non-convulsive seizures on EEG that resolve with intervention

or Raised intercranial pressure:

  • Focal/local edema on neuroimaging**

First occurrence of grade 3 ICANS

  • Withhold EPKINLY until ICANS resolves††
  • Administer dexamethasone‡‡ 10 mg intravenously every 6 hours. Continue dexamethasone use until resolution to grade 1 or less, then taper
  • Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management, including consideration for starting non-sedating, anti-seizure medicines for seizure prophylaxis
  • Provide supportive therapy, which may include intensive care

Recurrent grade 3 ICANS

  • Permanently discontinue EPKINLY
  • Administer dexamethasone‡‡ 10 mg intravenously every 6 hours. Continue dexamethasone use until resolution to grade 1 or less, then taper
  • Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management, including consideration for starting non-sedating, anti-seizure medicines for seizure prophylaxis
  • Provide supportive therapy, which may include intensive care

Grade 4

ICE score 0# or Depressed level of consciousness** either:

  • Patient is unarousable or requires vigorous or repetitive tactile stimuli to arouse, or
  • Stupor or coma

or Seizures,** either:

  • Life-threatening prolonged seizure (>5 minutes), or
  • Repetitive clinical or electrical seizures without return to baseline in between

or Motor findings**:

  • Deep focal motor weakness, such as hemiparesis or paraparesis

or Raised intracranial pressure/cerebral edema,** with signs/symptoms such as:

  • Diffuse cerebral edema on neuroimaging, or
  • Decerebrate or decorticate posturing, or
  • Cranial nerve VI palsy, or
  • Papilledema, or
  • Cushing’s triad
  • Permanently discontinue EPKINLY
  • Administer dexamethasone†† 10 mg intravenously every 6 hours. Continue dexamethasone use until resolution to grade 1 or less, then taper
  • Alternatively, consider administration of methylprednisolone 1000 mg per day intravenously and continue methylprednisolone 1000 mg per day intravenously for 2 or more days
  • Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management, including consideration for starting non-sedating, anti-seizure medicines for seizure prophylaxis
  • Provide supportive therapy, which may include intensive care

Presenting symptoms||

ICE score 7-9# or Depressed level of consciousness**:

  • Awakens spontaneously

Actions

  • Withhold EPKINLY until ICANS resolves††
  • Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management, including consideration for starting non-sedating, anti-seizure medicines for seizure prophylaxis

Manage CRS and ICANS according to the recommendations in the EPKINLY Dosage and Administration Section 2.6 of the Prescribing Information. Consider further management per current practice guidelines and provide supportive therapy, which may include intensive care.

For infections, grades 1-4

  • Withhold EPKINLY in patients with active infection, until the infection resolves‡
  • For grade 4, consider permanent discontinuation of EPKINLY

For other adverse reactions, grade 3 or higher

  • Withhold EPKINLY until the toxicity resolves to grade 1 or baseline‡

Neutropenia, absolute neutrophil count (ANC) <0.5 x 109/L

  • Withhold EPKINLY until ANC ≥0.5 x 109/L‡

Thrombocytopenia, platelet count <50 x 109/L

  • Withhold EPKINLY until platelet count ≥50 x 109/L‡

*Based on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading for CRS and ICANS.

†Premedication may mask fever; therefore, if clinical presentation is consistent with CRS, follow these management guidelines.

‡Refer to Table 2 in Section 2.3 of the Prescribing Information for information on restarting EPKINLY after dose delays.

§Low-flow oxygen defined as oxygen delivered at <6 L/minute; high-flow oxygen defined as oxygen delivered at ≥6 L/minute.

If grade 2 or 3 CRS occurs with the second full dose (48 mg) or beyond, administer CRS premedications with each subsequent dose until an EPKINLY dose is given without subsequent CRS of any grade. Refer to Table 3 in Section 2.3 of the Prescribing Information for additional information on premedication.

||Management is determined by the most severe event, not attributable to any other cause.

#If patient is arousable and able to perform Immune Effector Cell-Associated Encephalopathy (ICE) Assessment, assess: Orientation (oriented to year, month, city, hospital = 4 points); Naming (names 3 objects, eg, point to clock, pen, button = 3 points); Following Commands (eg, “show me 2 fingers” or “close your eyes and stick out your tongue” = 1 point); Writing (ability to write a standard sentence = 1 point); and Attention (count backwards from 100 by ten = 1 point). If patient is unarousable and unable to perform ICE Assessment (grade 4 ICANS) = 0 points.

**Not attributable to any other cause.

††See Table 2 in Section 2.3 of the Prescribing Information for recommendations on restarting EPKINLY after dose delays.

‡‡All references to dexamethasone administration are dexamethasone or equivalent.

BiPAP=bilevel positive airway pressure; CPAP=continuous positive airway pressure; CRS=cytokine release syndrome; ICANS=immune effector cell-associated neurotoxicity syndrome; IV=intravenous; SC=subcutaneous.

" "

Get support for EPKINLY for your practice and patients

See what’s offered

Download the Dosing and Administration Guide for more information on how EPKINLY is administered

Download now

Download the Adverse Reactions Management Guide for more information on dosing modifications and management for adverse events

Download now